EUVIMEDEUVIMED entdecken
Crossref

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study

Nipun Verma iD, Ajay Duseja iD, Manu Mehta, Arka De iD, Huapeng Lin, Vincent Wai-Sun Wong iD, Grace Lai-Hung Wong, Ruveena Bhavani Rajaram, Wah-Kheong Chan, Sanjiv Mahadeva iD, Ming-Hua Zheng iD, Wen-Yue Liu und 14 weitere

Alimentary Pharmacology & Therapeutics · 2024-03 · 59 (6) · 774-788

DOI: 10.1111/apt.17891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024-02. Verfasst von Nipun Verma und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The precise estimation of cases with significant fibrosis (SF) is an unmet goal in non‐alcoholic fatty liver disease (NAFLD/MASLD).

Aims

We evaluated the performance of machine learning (ML) and non‐patented scores for ruling out SF among NAFLD/MASLD patients.

Methods

Twenty‐one ML models were trained ( N = 1153), tested ( N = 283), and validated ( N = 220) on clinical and biochemical parameters of histologically‐proven NAFLD/MASLD patients ( N = 1656) collected across 14 centres in 8 Asian countries. Their performance for detecting histological‐SF (≥F2fibrosis) were evaluated with APRI, FIB4, NFS, BARD, and SAFE (NPV/F1‐score as model‐selection criteria).

Results

Patients aged 47 years (median), 54.6% males, 73.7% with metabolic syndrome, and 32.9% with histological‐SF were included in the study. Patients with SFvs.no‐SF had higher age, aminotransferases, fasting plasma glucose, metabolic syndrome, uncontrolled diabetes, and NAFLD activity score ( p < 0.001, each). ML models showed 7%–12% better discrimination than FIB‐4 to detect SF. Optimised random forest (RF) yielded best NPV/F1 in overall set (0.947/0.754), test set (0.798/0.588) and validation set (0.852/0.559), as compared to FIB4 in overall set (0.744/0.499), test set (0.722/0.456), and validation set (0.806/0.507). Compared to FIB‐4, RF could pick 10 times more patients with SF, reduce unnecessary referrals by 28%, and prevent missed referrals by 78%. Age, AST, ALT fasting plasma glucose, and platelet count were top features determining the SF. Sequential use of SAFE < 140 and FIB4 < 1.2 (when SAFE > 140) was next best in ruling out SF (NPV of 0.757, 0.724 and 0.827 in overall, test and validation set).

Conclusions

ML with clinical, anthropometric data and simple blood investigations perform better than FIB‐4 for ruling out SF in biopsy‐proven Asian NAFLD/MASLD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolic SyndromeMaleHumansFemaleLiver CirrhosisBlood GlucoseBiopsyFibrosisAsiaObesityAspartate AminotransferasesLiver

Stichwörter der Autor:innen

NASHartificial intelligencefatty liverliver fibrosismortality

Substanzen

Blood GlucoseAspartate Aminotransferases

Autor:innen und Institutionen

  • Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • NAFLD Research Centre Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Division of Gastroenterology, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Nipun Verma, Ajay Duseja, Arka De, Vincent Wai-Sun Wong, Sanjiv Mahadeva, Ming-Hua Zheng, Phunchai Charatcharoenwitthaya, Anand Kulkarni, Yeong Yeh Lee

Zitieren

APA

Verma, N., Duseja, A., Mehta, M., De, A., Lin, H., Wong, V. W., Wong, G. L., Rajaram, R. B., Chan, W. K., Mahadeva, S., Zheng, M. H., Liu, W. Y., Treeprasertsuk, S., Prasoppokakorn, T., Kakizaki, S., Seki, Y., Kasama, K., Charatcharoenwitthaya, P., Sathirawich, P., …, & Young, D. Y. (2024). Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study. Alimentary Pharmacology & Therapeutics, 59(6), 774-788. https://doi.org/10.1111/apt.17891

Vancouver

Verma N, Duseja A, Mehta M, De A, Lin H, Wong VW, et al. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study. Alimentary Pharmacology & Therapeutics. 2024;59(6):774-788. doi:10.1111/apt.17891

BibTeX
@article{Verma2024,
  author = {Verma, Nipun and Duseja, Ajay and Mehta, Manu and De, Arka and Lin, Huapeng and Wong, Vincent Wai-Sun and Wong, Grace Lai-Hung and Rajaram, Ruveena Bhavani and Chan, Wah-Kheong and Mahadeva, Sanjiv and Zheng, Ming-Hua and Liu, Wen-Yue and Treeprasertsuk, Sombat and Prasoppokakorn, Thaninee and Kakizaki, Satoru and Seki, Yosuke and Kasama, Kazunori and Charatcharoenwitthaya, Phunchai and Sathirawich, Phalath and Kulkarni, Anand and Purnomo, Hery Djagat and Kamani, Lubna and Lee, Yeong Yeh and Wong, Mung Seong and Tan, Eunice X X and Young, Dan Yock},
  title = {Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {6},
  pages = {774--788},
  doi = {10.1111/apt.17891}
}
Kostenlos starten →